Roti prata, keep flipping._老虎社区_美港股上老虎

2021-09-10

Roti prata, keep flipping.

Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":883434331,"tweetId":"883434331","gmtCreate":1631262386823,"gmtModify":1631892936482,"author":{"id":3583974841960176,"idStr":"3583974841960176","authorId":3583974841960176,"authorIdStr":"3583974841960176","name":"CIG","avatar":"https://static.tigerbbs.com/6c2077e2370e1ffcaca7e29b875be2be","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":95,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Roti prata, keep flipping.</body></html>","htmlText":"<html><head></head><body>Roti prata, keep flipping.</body></html>","text":"Roti prata, keep flipping.","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/883434331","repostId":1158877090,"repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://www.laohu8.com/m/news/1158877090?lang=zh_CN&edition=full","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"(Update: Sept 10, 2021 at 04:14 a.m. ET)<blockquote>（更新：美国东部时间2021年9月10日凌晨04:14）</blockquote> Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump. Key Points<blockquote>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。要点</blockquote> <ul> <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li> <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li> <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> What happened<blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul>发生了什么</blockquote> Shares of&nbsp;<a href=\"https://laohu8.com/S/NVAX\">Novavax</a> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;The Economic Times&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).<blockquote>本公司之股份<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在经济时报印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote> So what<blockquote>那又怎样</blockquote> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times&nbsp;article.<blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据经济时报文章。</blockquote> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.<blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.<blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote> Now what<blockquote>现在怎么办</blockquote> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.<blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote> Novavax fell over 2% in premarket trading.<blockquote>Novavax在盘前交易中下跌超过2%。</blockquote> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-10 15:31\n\n</h4>\n</header>\n<article>\n(Update: Sept 10, 2021 at 04:14 a.m. ET)<blockquote>（更新：美国东部时间2021年9月10日凌晨04:14）</blockquote> Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump. Key Points<blockquote>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。要点</blockquote> <ul> <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li> <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li> <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> What happened<blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul>发生了什么</blockquote> Shares of&nbsp;<a href=\"https://laohu8.com/S/NVAX\">Novavax</a> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;The Economic Times&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).<blockquote>本公司之股份<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在经济时报印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote> So what<blockquote>那又怎样</blockquote> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times&nbsp;article.<blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据经济时报文章。</blockquote> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.<blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.<blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote> Now what<blockquote>现在怎么办</blockquote> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.<blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote> Novavax fell over 2% in premarket trading.<blockquote>Novavax在盘前交易中下跌超过2%。</blockquote> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":544,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/883434331"}